Blockchain Registration Transaction Record

Clene Inc. Makes Strides in Developing CNM-Au8 to Address Neurodegenerative Conditions

Clene Inc. presents new findings and information about the company and its lead drug candidate CNM-Au8 at the Emerging Growth Conference 73, showcasing significant strides in developing potential treatments for neurodegenerative diseases.

This news matters as it highlights the significant strides made by Clene Inc. in developing CNM-Au8 as a potential treatment for neurodegenerative diseases, which have limited current treatment options. The company's research and findings presented at the Emerging Growth Conference 73 demonstrate promising developments in the ALS treatment market, which is poised for growth due to an aging population.